Responses
Regular and Young Investigator Award Abstracts
Clinical Trials In Progress
393 A phase 1/2 study of SBT6050 combined with trastuzumab deruxtecan (T-DXd) or trastuzumab and tucatinib with or without capecitabine in patients with HER2-expressing or HER2-amplified cancers
Compose a Response to This Article
Other responses
No responses have been published for this article.